Claims
- 1. A method of altering the level of secretion of FSH in a vertebrate animal, comprising administering to the animal an effective amount of a peptide selected from the group consisting of an l-LHRH-III agonist peptide; an l-LHRH-III superagonist peptide; an l-LHRH-III antagonist peptide; a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41; and l-LHRH-III (SEQ. ID NO. 1); wherein the amount of the peptide administered causes a selective change in the serum FSH level of the animal, but does not cause a proportional change in the serum LH level of the animal.
- 2. A method as recited in claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of l-LHRH-III (SEQ. ID No. 1).
- 3. A method as recited in claim 2, wherein the animal is a mammal.
- 4. A method as recited in claim 3, wherein the animal is a human.
- 5. A method as recited in claim 4, wherein the human is male.
- 6. A method as recited in claim 4, wherein the human is female.
- 7. A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of claim 2.
- 8. A method as recited in claim 7, wherein the animal is a mammal.
- 9. A method as recited in claim 8, wherein the animal is a human.
- 10. A method as recited in claim 9, wherein the human is male.
- 11. A method as recited in claim 9, wherein the human is female.
- 12. A method as recited in claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of an l-LHRH-III agonist peptide or l-LHRH-III superagonist peptide; wherein the amount of the peptide administered causes a selective increase in the serum FSH level of the animal, but does not cause a proportional increase in the serum LH level of the animal.
- 13. A method as recited in claim 12, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of l-LHRH-III (SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of l-LHRH-III is deleted.
- 14. A method as recited in claim 13, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.
- 15. A method as recited in claim 12, wherein the animal is a mammal.
- 16. A method as recited in claim 15, wherein the animal is a human.
- 17. A method as recited in claim 16, wherein the human is male.
- 18. A method as recited in claim 16, wherein the human is female.
- 19. A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of claim 12.
- 20. A method as recited in claim 19, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of l-LHRH-III (SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of l-LHRH-III is deleted.
- 21. A method as recited in claim 20, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.
- 22. A method as recited in claim 19, wherein the animal is a mammal.
- 23. A method as recited in claim 19, wherein the animal is a human.
- 24. A method as recited in claim 23, wherein the human is male.
- 25. A method as recited in claim 23, wherein the human is female.
- 26. A method as recited in claim 1, wherein the level of secretion of FSH in the animal is decreased; said method comprising administering to the animal an effective amount of an l-LHRH-III antagonist peptide; wherein the amount of the peptide administered causes a selective decrease in the serum FSH level of the animal, but does not cause a proportional decrease in the serum LH level of the animal.
- 27. A method as recited in claim 26, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.
- 28. A method as recited in claim 26, wherein the animal is a mammal.
- 29. A method as recited in claim 28, wherein the animal is a human.
- 30. A method as recited in claim 29, wherein the human is male.
- 31. A method as recited in claim 29, wherein the human is female.
- 32. A method of decreasing the fertility of a vertebrate animal, comprising decreasing the level of FSH secretion in the animal by the method of claim 26.
- 33. A method as recited in claim 32, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.
- 34. A method as recited in claim 32, wherein the animal is a mammal.
- 35. A method as recited in claim 34, wherein the animal is a human.
- 36. A method as recited in claim 35, wherein the human is male.
- 37. A method as recited in claim 35, wherein the human is female.
- 38. A composition selected from the group consisting of an l-LHRH-III agonist peptide; an l-LHRH-III superagonist peptide; an I-LHRH-III antagonist peptide; a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41; and an effective amount of substantially pure l-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier; wherein said composition has the property that said composition will, when administered in an effective amount to a vertebrate animal, cause a selective change in the serum FSH level of the animal, but will not cause a proportional change in the serum LH level of the animal.
- 39. A composition as recited in claim 38, wherein said composition comprises an effective amount of substantially pure l-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier.
- 40. A composition as recited in claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.
- 41. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 6.
- 42. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 7.
- 43. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 8.
- 44. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 9.
- 45. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 10.
- 46. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 11.
- 47. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 12.
- 48. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 13.
- 49. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 14.
- 50. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 15.
- 51. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 16.
- 52. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 17.
- 53. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 18.
- 54. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 19.
- 55. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 20.
- 56. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 21.
- 57. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 22.
- 58. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 23.
- 59. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 24.\
- 60. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 25.
- 61. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 26.
- 62. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 27.
- 63. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 28.
- 64. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 29.
- 65. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 30.
- 66. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 31.
- 67. A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 32.
- 68. A composition as recited in claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.
- 69. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 33.
- 70. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 34.
- 71. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 35.
- 72. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 36.
- 73. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 37.
- 74. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 38.
- 75. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 39.
- 76. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 40.
- 77. A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 41.
Parent Case Info
[0001] The benefit of the Jun. 4, 1997 filing date of provisional application serial No. 60/091,112 (which was a conversion of nonprovisional application Ser. No. 08/869,153) is claimed under 35 U.S.C. §119(e) in the United States. The benefit of the Jun. 4, 1997 filing date of application Ser. No. 08/869,153 is claimed under applicable treaties and conventions outside the United States.
Government Interests
[0002] This invention was made with support from the United States Government under Grants DK43900 and MH51853 awarded by the National Institutes of Health. The United States Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60092112 |
Jun 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09297989 |
May 1999 |
US |
Child |
10109331 |
Mar 2002 |
US |